Ophtec Receives CE Mark Approval for Artiplus Phakic IOL for Presbyopia

Ophtec announced it has received CE Mark approval for its Artiplus Phakic IOL, which is designed for young presbyopes, typically in their early 40s. The Artiplus lens is designed to provide clear vision at all distances, eliminating the need for reading glasses or other corrective eyewear.

This cutting-edge technology, built on Ophtec's Artiflex platform, introduces a patented multi-segmented optic system known as CTF technology. The design generates multiple elongated focal points, delivering sharp vision with smooth transitions across all distances, according to Ophtec. 

The CE Mark approval follows the success of an international clinical study conducted in nine countries. Patients experienced outstanding visual acuity for distance, intermediate, and near vision without the need for corrective lenses.

"We are thrilled to introduce Artiplus as a new treatment option for presbyopia," Tiago Guerreiro, Global Product Manager at Ophtec, said in a company news release. "Many people in their 40s are frustrated with the limitations of reading glasses or are struggling with multifocal glasses. Traditional presbyopia treatments, like laser surgery, are not sufficient for many patients. Artiplus offers a compelling solution for those seeking to regain high quality of vision at all distances."

The lead investigator of the international study, Professor Dr. José Güell, highlighted the exceptional outcomes: "The 1-year follow-up data for uncorrected visual acuity at all distances were extraordinarily positive. The consistency of results is remarkable, solidifying Artiplus as a game-changer in presbyopia treatment."

Ophtec said Artiplus has already shown strong performance in South Korea, where it has been available to patients. 

For more information on the Artiplus Phakic IOL and its availability, visit www.ophtec.com.